A prostaglandin E2 receptor subtype EP1-selective antagonist, ONO-8711, suppresses 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesis

Carcinogenesis

Volumn 28, Issue 3, 2007, Pages 677-684

  Makita, Hiroki ^a   Mutoh, Michihiro ^b   Maruyama, Takayuki ^c   Yonemoto, Kazuhiro ^a   Kobayashi, Atsushi ^a   Fujitsuka, Hideki ^a   Toida, Makoto ^a   Shibata, Toshiyuki ^a   Miyamoto, Shingo ^d,e   Yasui, Yumiko ^d   Suzuki, Rikako ^b   Wakabayashi, Keiji ^b   Tanaka, Takuji ^d  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c ONO PHARMACEUTICAL CO   (Japan)

^d KANAZAWA MEDICAL UNIVERSITY   (Japan)

^e KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROQUINOLINE 1 OXIDE; 6 [3 (4 CHLORO 2 METHYLPHENYLSULFONYLAMINOMETHYL)BICYCLO[2.2.2]OCTAN 2 YL] 5 HEXENOIC ACID; DRINKING WATER; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; BICYCLO COMPOUND; CARCINOGEN; HEXANOIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INCIDENCE; CANCER INHIBITION; CARCINOGENESIS; CELL ACTIVITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EPITHELIUM CELL; FISCHER 344 RAT; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SQUAMOUS CELL CARCINOMA; TONGUE CANCER; TREATMENT DURATION; ANIMAL; ANIMAL FOOD; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; METABOLISM; PATHOLOGY; PRECANCER; TONGUE; TONGUE TUMOR;

4-NITROQUINOLINE-1-OXIDE; ANIMAL FEED; ANIMALS; BICYCLO COMPOUNDS; CARCINOGENS; CARCINOMA, SQUAMOUS CELL; DINOPROSTONE; HEXANOIC ACIDS; MALE; PRECANCEROUS CONDITIONS; RATS; RATS, INBRED F344; RECEPTORS, PROSTAGLANDIN E; TONGUE; TONGUE NEOPLASMS;

EID: 34047103462     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgl178     Document Type: Article

References (44)

1. Mignogna,M.D., Fedele,S. and Russo,L.L. (2004) The world cancer report and the burden of oral cancer. Eur. J. Cancer Prev., 13, 139-142.
2. Blot,W.J., McLaughlin,J.K., Winn,D.M., Austin,D.F., Greenberg,R.S., Preston-Martin,S., Bernstein,L., Schoenberg,J.B., Stemhargen,A. and Fraumeni,J.F.J. (1988) Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res., 48, 3282-3287.
3. Tanaka,T. (1995) Chemoprevention of oral carcinogenesis. Eur. J. Cancer B Oral Oncol., 31B, 3-15.
4. Nair,U., Bartsch,H. and Nair,J. (2004) Alert for an epidemic of oral cancer due to use of the betel quid substitutes gutkha and pan masala: A review of agents and causative mechanisms. Mutagenesis, 19, 251-262.
5. Mackenzie,J., Ah-See,K., Thankker,N., Sloan,P., Maran,A.G., Birch,J. and Macfarlane,G.J. (2000) Increasing incidence of oral cancer amongst young person: What is the aetiology? Oral Oncol., 36, 387-389.
6. Day,G.L. and Blot,W.J. (1992) Second primary tumors in patients with oral cancer. Cancer, 70, 14-19.
7. Lindblad,M., Lagergren,J. and Garcia Rodriguez,L.A. (2005) Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol. Biomarkers Prev., 14, 444-450.
8. Garcia Rodriguez,L.A. and Gonzalez-Perez,A. (2004) Risk of breast cancer among users of aspirin and other anti-inflammatory drugs. Br. J. Cancer, 91, 525-529.
9. Sorensen,H.T., Friis,S., Norgard,B., Mellemkjaer,L., Blot,W.J., McLaughlin,J.K., Ekbom,A. and Baron,J.A. (2003) Risk of cancer in a large cohort of nonaspirin NSAID users: A population-based study. Br. J. Cancer, 88, 1687-1692.
10. Bosetti,C., Talamini,R., Franceschi,S., Negr,I.E., Garavello,W. and La Vecchia,C. (2003) Aspirin use and cancers of the upper aerodigestive tract. Br. J. Cancer, 88, 672-674.
11. Farrow,D.C., Vaughan,T.L., Hansten,P.D. et al. (1998) Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol. Biomarkers Prev., 7, 97-102.
12. Porteder,H., Matejka,M., Ulrich,W. and Sinzinger,H. (1984) The cyclo-oxygenase and lipoxygenase pathways in human oral cancer tissue. J. Maxillofac. Surg., 12, 145-147.
13. Yanaida,Y., Kohno,H., Yoshida,K., Hirose,Y., Yamada,Y., Mori,H. and Tanaka,T. (2002) Dietary silymarin suppresses 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in male F344 rats. Carcinogenesis, 23, 787-794.
14. Jung,T.T., Berlinger,N.T. and Juhn,S.K. (1985) Prostaglandins in squamous cell carcinoma of the head and neck: A preliminary study. Laryngoscope, 95, 307-312.
15. Chan,G., Boyle,J.O., Yang,E.K. et al. (1999) Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res., 59, 991-994.
16. Renkonen,J., Wolff,H. and Paavonen,T. (2002) Expression of cyclooxygenase-2 in human tongue carcinoma and its precursor lesions. Virchows Arch., 440, 594-597.
17. Kitamura,T., Kawamori,T., Uchiya,N., Itoh,M., Noda,T., Matsuura,M., Sugimura,T. and Wakabayashi,K. (2002) Inhibitory effects of mofezolac, a cyclooxygenase-1 selective inhibitor, on intestinal carcinogenesis. Carcinogenesis, 23, 1463-1466.
18. Dannenberg,A.J., Altorki,N.K., Boyle,J.O., Dang,C., Howe,L.R., Weksler,B.B. and Subbaramaiah,K. (2001) Cyclo-oxygenase 2: A pharmacological target for the prevention of cancer. Lancet Oncol., 2, 544-551.
19. Konturek,P.C., Kania,J., Burnat,G., Hahn,E.G. and Konturek,S.J. (2005) Prostaglandins as mediators of COX-2 derived carcinogenesis in gastrointestinal tract. J. Physiol. Pharmacol., 56 (Suppl. 5), 57-73.
20. Sudbo,J., Ristimaki,A., Sondresen,J.E., Kildal,W., Boysen,M., Koppang,H.S., Reith,A., Risberg,B., Nesland,J.M. and Bryne,M. (2003) Cyclooxygenase-2 (COX-2) experssion in high-risk premalignant oral lesion. Oral Oncol., 39, 497-505.
21. Nishimura,N., Urada,M., Hashitani,S., Noguchi,K., Manno,Y., Takaoka,K. and Sakura,K. (2004) Increased expression of cyclooxygenase (COX)-2 in DMBA-induced hamster cheek pouch carcinogenesis and chemopreventive effect of a selective COX-2 inhibitor celecoxib. J. Oral Pathol. Med., 33, 614-621.
22. Yoshida,K., Tanaka,T., Kohno,H., Sakata,K., Kawamori,T., Mori,H. and Wakabayashi,K. (2003) A COX-2 inhibitor, nimesulide, inhibits chemically induced rat tongue carcinogenesis through suppression of cell proliferation activity and COX-2 and iNOS expression. Histol. Histopathol., 18, 39-48.
23. Yamamoto,K., Kitayama,W., Denda,A., Morisaki,A., Kuniyasu,H., Inoue,M. and Kirita,T. (2003) Inhibitory effects of selective cyclooxygenase-2 inhibitors, nimesulide and etodolac, on the development of squamous cell dysplasias and carcinomas of the tongue in rats initiated with 4-nitroquinoline 1-oxide. Cancer Lett., 199, 121-129.
24. Yamamoto,K., Kitayama,W., Denda,A., Morisaki,A., Kuniyasu,H., Inoue,M. and Kirita,T. (2004) Supperssive effects of a selective cyclooxygenase-2 inhibitor, etodolac, on 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesis. Exp. Toxicol. Pathol., 56, 145-151.
25. Shiotani,H., Denda,A., Yamamoto,K., Kitayama,W., Endoh,T., Sasaki,Y., Tsutsumi,N., Sugiyama,M. and Konishi,Y. (2001) Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide. Cancer Res., 61, 1451-1456.
26. Solomon,S.D., McMurray,J.J., Pfeffer,M.A., Wittes,J., Fowler,R., Finn,P., Anderson,W.F., Zauber,A., Hawk,E. and Bertagnolli,M. (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med., 352, 1071-1080.
27. Coleman,R.A., Smith,W.L. and Narumiya,S. (1994) International Union of Pharmacology classification of prostanoid receptors: Properties, distribution, and structure of the receptors and their subtype. Pharmacol. Rev., 46, 205-229.
28. Watanabe,K., Kawamori,T., Nakatsugi,S. et al. (1999) Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res., 59, 5093-5096.
29. Mutoh,M., Watanabe,K., Kitamura,T. et al. (2002) Involvement of prostaglandin E receptor subtype EP4 in colon carcinogenesis. Cancer Res., 62, 28-32.
30. Shoji,Y., Takahashi,M., Kitamura,T. et al. (2004) Downregulation of prostaglandin E receptor subtype EP3 during colon cancer development. Gut, 53, 1151-1158.
31. 3 deficiency modifies tumor outcome in mouse two-stage skin carcinogenesis. Carcinogenesis, 26, 2116-2122.
32. 1 antagonist, on breast cancer development. Carcinogenesis, 22, 2001-2004.
33. Niho,N., Mutoh,M., Kitamura,T., Takahashi,M., Sato,H., Yamamoto,H., Maruyama,T., Ohuchida,S., Sugiyama,T. and Wakabayashi,K. (2005) Suppression of azoxymethane-induced colon cancer development in rats by a prostaglandin E receptor EP1-selective antagonist. Cancer Sci., 96, 260-264.
34. Takahashi,M. and Wakabayashi,K. (2004) Gene mutations and altered gene expression in azoxymethane-induced colon carcinogenesis in rodents. Cancer Sci., 95, 475-480.
35. Kramer,I.R., Lucas,R.B., Pindborg,J.J. and Sobin,L.H. (1978) Definition of leukoplakia and related lesions: An aid to studies on oral precancer. Oral Surg. Oral Med. Oral Pathol., 46, 518-539.
36. 4 antagonists on intestinal tumorigenesis in adenomatous poliposis coli gene knockout mice. Cancer Sci., 94, 618-621.
37. 1 deficiency inhibits colon cancer development. Carcinogenesis, 26, 353-357.
38. Chen,Y.K. and Lin,L.M. (2000) Immunohistochemical expression of inducible nitric oxide synthase in DMBA-induced hamster buccal pouch carcinogenesis. Oral Oncol., 36, 221-224.
39. Mognetti,B., Di Carlo,F. and Berta,G.N. (2006) Animal models in oral cancer research. Oral Oncol., 42, 448-460.
40. 2 in adult human epidermis. J. Invest. Dermatol., 124, 965-970.
41. 1 receptor in cutaneous UVB-induced inflammation and tumor development. J. Invest. Dermatol., 126, 205-211.
42. Mori,H., Sugie,S., Yoshimi,N., Hara,A. and Tanaka,T. (1999) Control of cell proliferation in cancer prevention. Mutat. Res., 428, 291-298.
43. Breyer,R.M., Bagdassarian,C.K., Myers,S.A. and Breyer,M.D. (2001) Prostanoid receptors: Subtypes and signaling. Annu. Rev. Pharmacol. Toxicol., 41, 661-690.
44. Yuspa,S.H. (1994) The pathogenesis of squamous cell cancer: Lessons learned from studies of skin carcinogenesis-thirty-third G. H. A. Clowes Memorial Award Lecture. Cancer Res., 54, 1178-1189.